Medtronic (MDT) announced that the Centers for Medicare & Medicaid Services, or CMS, has released the final National Coverage Determination, or NCD, on renal denervation, applicable to the Symplicity Spyral renal denervation, or RDN, system, also known as the Symplicity blood pressure procedure. This final determination will now provide Medicare patients with access to the Symplicity blood pressure procedure for the treatment of uncontrolled hypertension, or high blood pressure. The Symplicity Spyral RDN system, approved by the FDA in November 2023, is an innovative, minimally invasive procedure that delivers radiofrequency energy to nerves near the kidneys that can become overactive and contribute to high blood pressure. The Symplicity Spyral RDN system is approved for commercial use in nearly 80 countries around the world.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic’s Promising RDN Trial Results and Market Growth Potential Drive Buy Rating
- Medtronic’s Symplicity Spyral System: A Promising Growth Opportunity with Proven Efficacy
- Medtronic announces new results from final report of SPYRAL HTN-ON MED
- Wells Fargo sees no change to Medtronic’s bullish CAS outlook
- Medtronic’s AGM Approves Key Governance Changes